• 1. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 2. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 3. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 4. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 5. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608

Introduction to 4,6-Dichloro-3-(difluoromethyl)pyridin-2-amine (CAS No. 1805969-44-1)

4,6-Dichloro-3-(difluoromethyl)pyridin-2-amine (CAS No. 1805969-44-1) is a versatile compound with significant potential in the fields of medicinal chemistry and pharmaceutical research. This compound is characterized by its unique structural features, including dichloro and difluoromethyl substituents on a pyridine ring, which contribute to its chemical stability and biological activity.

The synthesis of 4,6-Dichloro-3-(difluoromethyl)pyridin-2-amine has been extensively studied due to its importance in the development of novel therapeutic agents. Recent advancements in synthetic methodologies have enabled the efficient and scalable production of this compound, making it more accessible for various applications. One notable approach involves the use of transition-metal-catalyzed reactions, which have shown high yields and selectivity.

In terms of its biological activity, 4,6-Dichloro-3-(difluoromethyl)pyridin-2-amine has been evaluated for its potential as a lead compound in drug discovery. Studies have demonstrated that this compound exhibits potent inhibitory effects on specific enzymes and receptors, making it a valuable candidate for the treatment of various diseases. For instance, it has shown promising activity against kinases involved in cancer pathways, suggesting its potential as an anticancer agent.

Moreover, the pharmacokinetic properties of 4,6-Dichloro-3-(difluoromethyl)pyridin-2-amine have been investigated to assess its suitability for in vivo applications. Preclinical studies have indicated that this compound has favorable absorption, distribution, metabolism, and excretion (ADME) profiles, which are crucial for its therapeutic efficacy. Additionally, its low toxicity and high selectivity towards target proteins further enhance its attractiveness as a drug candidate.

The structural versatility of 4,6-Dichloro-3-(difluoromethyl)pyridin-2-amine allows for the modification of its functional groups to optimize its biological activity and pharmacological properties. Researchers have explored various derivatives by introducing different substituents at the pyridine ring or modifying the difluoromethyl group. These modifications have led to the discovery of compounds with enhanced potency and improved pharmacokinetic profiles.

In the context of medicinal chemistry, 4,6-Dichloro-3-(difluoromethyl)pyridin-2-amine serves as a valuable scaffold for the design and synthesis of novel drugs. Its unique combination of functional groups provides a robust platform for structure-based drug design (SBDD) and rational drug discovery. Computational methods such as molecular docking and molecular dynamics simulations have been employed to predict the binding modes and interactions of this compound with target proteins, guiding the optimization process.

Clinical trials are an essential step in evaluating the safety and efficacy of new drugs. While specific clinical data on 4,6-Dichloro-3-(difluoromethyl)pyridin-2-amine may be limited at present, preclinical studies have laid a strong foundation for its potential advancement to clinical trials. Ongoing research aims to address key challenges such as improving solubility and stability while maintaining or enhancing biological activity.

In conclusion, 4,6-Dichloro-3-(difluoromethyl)pyridin-2-amine (CAS No. 1805969-44-1) is a promising compound with significant potential in medicinal chemistry and pharmaceutical research. Its unique structural features, biological activity, and favorable pharmacokinetic properties make it an attractive candidate for further development as a therapeutic agent. Continued research and innovation will likely uncover new applications and optimize its use in various medical fields.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)